Clinical trial

Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt

NCT05423769

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Fingolimod Normalized identity: fingolimodView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2022-01-19

PhaseN/A

Conditions

Relapsing-Remitting Multiple Sclerosisverified · MONDO: relapsing-remitting multiple sclerosis

Interventions

FingolimodDRUG · verified · RxNorm: fingolimod

Sponsors & collaborators

Hikma Pharmaceuticals LLClead sponsor

Mapped research locations

CairoEgypt1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05423769 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.